Hospital
Milford Regional Medical Center INC
Milford Regional Medical Center INC was paid $48.59M by Medicaid between Jan 2018 and Dec 2024, across 373 billing codes. Its largest line is 99285, emergency room visit (most serious) — 13% of everything it billed.
33Billing provider infoMILFORD REGIONAL MEDICAL CENTER INC
MILFORD, MA 01757
MILFORD, MA 01757
33aNPI1477527497assigned 02/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$48.59M
24GClaims1,787,227
24DCodes billed373
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#24 of 66
Median peer was paid$29.11M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 229,794 | $6.37M | |
| 2019 | 230,682 | $6.08M | |
| 2020 | 201,271 | $5.21M | |
| 2021 | 271,519 | $7.13M | |
| 2022 | 310,573 | $9.39M | |
| 2023 | 308,452 | $7.32M | |
| 2024incomplete | 234,936 | $7.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 45,662 | 40,310 | $6.48M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 16,716 | 14,841 | $5.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.7% | 29,927 | 28,449 | $4.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.1% | 31,184 | 28,877 | $3.93M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.8% | 55,028 | 14,604 | $3.32M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 12,490 | 8,599 | $1.25M |
| G0378 | Hospital observation service, per hour | 2.4% | 18,016 | 8,782 | $1.16M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 19,024 | 17,074 | $1.06M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 8,736 | 8,227 | $1.06M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.0% | 8,450 | 7,929 | $959K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 9,304 | 8,568 | $845K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.5% | 31,881 | 9,889 | $743K |
361 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 4,749 | $679K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 6,654 | $659K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 1,361 | $647K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 5,695 | $600K |
| 87631 | 1.1% | 6,258 | $533K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.0% | 1,041 | $491K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,287 | $481K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 737 | $474K |
| 93976 | <1% | 3,374 | $432K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23,755 | $416K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 98,145 | $413K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,232 | $399K |
| 93971 | <1% | 2,584 | $367K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,410 | $362K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16,107 | $284K |
| 97161 | <1% | 4,398 | $279K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 34,518 | $276K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,040 | $273K |
| 76830 | Ultrasound, transvaginal | <1% | 3,269 | $262K |
| 93975 | <1% | 2,409 | $254K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,854 | $253K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,840 | $252K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,838 | $252K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,747 | $238K |
| 84702 | <1% | 21,002 | $227K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,323 | $223K |
| 76770 | <1% | 1,725 | $207K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,007 | $198K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 82,569 | $173K |
| ATP08 | <1% | 25,249 | $163K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,613 | $156K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,884 | $141K |
| 84484 | <1% | 20,281 | $138K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 809 | $137K |
| 76642 | <1% | 1,800 | $130K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,906 | $119K |
| 76536 | <1% | 1,289 | $113K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,396 | $110K |
| 87088 | <1% | 23,291 | $105K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 7,378 | $104K |
| 87070 | <1% | 18,095 | $104K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 26,360 | $102K |
| 73630 | <1% | 4,003 | $100K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 468 | $97K |
| ATP15 | <1% | 11,406 | $96K | |
| 71250 | <1% | 1,750 | $95K | |
| 97162 | <1% | 1,728 | $95K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 122 | $93K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,668 | $92K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,056 | $89K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,433 | $88K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,210 | $87K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 432 | $85K |
| 74018 | <1% | 3,439 | $83K | |
| 73564 | <1% | 3,377 | $81K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 23,343 | $80K |
| 85027 | <1% | 26,628 | $80K | |
| 70496 | <1% | 686 | $78K | |
| 80053 | Comprehensive metabolic panel | <1% | 37,613 | $77K |
| 59025 | Fetal non-stress test | <1% | 356 | $72K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 31,409 | $71K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,159 | $71K |
| 83690 | <1% | 15,896 | $69K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,935 | $68K |
| ATP14 | <1% | 11,505 | $67K | |
| 72100 | <1% | 2,869 | $67K | |
| 73610 | <1% | 2,972 | $67K | |
| 81001 | <1% | 34,919 | $67K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,257 | $66K |
| 76641 | <1% | 382 | $63K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,150 | $63K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,216 | $62K |
| ATP17 | <1% | 8,882 | $61K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,071 | $60K |
| 93017 | <1% | 518 | $58K | |
| 82728 | <1% | 8,496 | $57K | |
| 86618 | <1% | 3,931 | $54K | |
| 87653 | <1% | 1,916 | $54K | |
| 83735 | <1% | 16,472 | $53K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 156 | $53K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 608 | $52K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,745 | $52K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 481 | $51K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,452 | $51K |
| 87077 | <1% | 10,756 | $51K | |
| 94664 | <1% | 1,501 | $50K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,708 | $49K |
| 73130 | <1% | 2,215 | $49K | |
| 73030 | <1% | 2,516 | $47K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 388 | $45K |
| 82607 | <1% | 6,706 | $43K | |
| 83880 | <1% | 3,814 | $43K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,940 | $42K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,072 | $42K |
| 86803 | <1% | 5,203 | $42K | |
| 97014 | <1% | 492 | $41K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 371 | $40K |
| 73110 | <1% | 1,759 | $39K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 438 | $37K |
| 87186 | <1% | 7,476 | $37K | |
| 80306 | <1% | 5,846 | $36K | |
| 82948 | <1% | 13,059 | $34K | |
| 84439 | <1% | 7,631 | $34K | |
| 93970 | <1% | 235 | $32K | |
| 97803 | <1% | 645 | $32K | |
| 80061 | Lipid panel | <1% | 33,676 | $31K |
| 86850 | <1% | 4,974 | $31K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 213 | $31K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,501 | $30K |
| 71271 | <1% | 940 | $30K | |
| 80076 | <1% | 24,426 | $29K | |
| 72141 | <1% | 142 | $29K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,060 | $29K |
| 73502 | <1% | 1,572 | $28K | |
| 85610 | <1% | 18,135 | $27K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,524 | $27K |
| 36415 | Collection of venous blood by venipuncture | <1% | 160,251 | $25K |
| 84153 | <1% | 2,978 | $24K | |
| 97802 | <1% | 628 | $24K | |
| 77066 | Tomosynthesis, mammo | <1% | 854 | $24K |
| 87205 | <1% | 7,945 | $23K | |
| 87400 | <1% | 1,789 | $22K | |
| 84703 | <1% | 3,395 | $22K | |
| 86140 | <1% | 8,156 | $22K | |
| 29125 | <1% | 181 | $22K | |
| 77080 | <1% | 492 | $20K | |
| 90785 | <1% | 627 | $20K | |
| 85730 | <1% | 6,451 | $20K | |
| 87040 | <1% | 2,807 | $19K | |
| 83540 | <1% | 6,114 | $19K | |
| 85651 | <1% | 8,831 | $18K | |
| 77065 | Tomosynthesis, mammo | <1% | 536 | $18K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 696 | $17K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,547 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,095 | $17K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 797 | $17K |
| 74019 | <1% | 915 | $16K | |
| 82784 | <1% | 2,021 | $16K | |
| 77062 | <1% | 194 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 976 | $16K |
| 12001 | <1% | 84 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,320 | $16K |
| 72050 | <1% | 457 | $16K | |
| 76870 | <1% | 190 | $15K | |
| ATP11 | <1% | 3,190 | $15K | |
| 97165 | <1% | 229 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,391 | $14K |
| 84403 | <1% | 1,186 | $14K | |
| 86900 | <1% | 6,244 | $14K | |
| 90715 | <1% | 630 | $13K | |
| 29515 | <1% | 93 | $13K | |
| 82746 | <1% | 2,052 | $13K | |
| 83655 | <1% | 1,440 | $13K | |
| ATP03 | <1% | 3,217 | $12K | |
| 82570 | <1% | 5,928 | $12K | |
| 83550 | <1% | 3,909 | $12K | |
| 73140 | <1% | 453 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,192 | $12K |
| 85378 | <1% | 2,098 | $12K | |
| ATP18 | <1% | 2,187 | $12K | |
| 87340 | <1% | 1,872 | $12K | |
| 86901 | <1% | 5,588 | $12K | |
| 82805 | <1% | 456 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 458 | $11K |
| 86780 | <1% | 1,705 | $11K | |
| 83970 | <1% | 770 | $11K | |
| 82043 | <1% | 4,633 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,433 | $10K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 276 | $10K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $10K |
| 83721 | <1% | 6,474 | $10K | |
| 86762 | <1% | 958 | $10K | |
| 73080 | <1% | 518 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,594 | $10K |
| 92526 | <1% | 152 | $10K | |
| 86787 | <1% | 1,000 | $9K | |
| 76882 | <1% | 115 | $9K | |
| 70491 | <1% | 99 | $8K | |
| 97116 | <1% | 422 | $8K | |
| 93308 | <1% | 38 | $8K | |
| 94060 | <1% | 136 | $8K | |
| 36406 | <1% | 391 | $7K | |
| 80074 | <1% | 314 | $7K | |
| 76775 | <1% | 107 | $7K | |
| ATP07 | <1% | 1,309 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 60 | $7K |
| 86480 | <1% | 184 | $7K | |
| 87046 | <1% | 733 | $7K | |
| 84466 | <1% | 909 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,393 | $7K |
| 88342 | <1% | 1,567 | $7K | |
| 86592 | <1% | 2,045 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,629 | $7K |
| 87147 | <1% | 1,691 | $6K | |
| 70486 | <1% | 243 | $6K | |
| ATP13 | <1% | 1,053 | $6K | |
| 94726 | <1% | 188 | $6K | |
| 86706 | <1% | 939 | $6K | |
| ATP10 | <1% | 1,612 | $6K | |
| 86038 | <1% | 900 | $6K | |
| 85007 | <1% | 4,247 | $6K | |
| ATP05 | <1% | 1,235 | $6K | |
| ATP04 | <1% | 1,146 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,698 | $5K |
| 80164 | <1% | 1,382 | $5K | |
| 83516 | <1% | 492 | $5K | |
| 81003 | <1% | 4,606 | $5K | |
| 80050 | General health panel | <1% | 287 | $5K |
| 87641 | <1% | 423 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,006 | $5K |
| 94729 | <1% | 226 | $5K | |
| 84402 | <1% | 367 | $5K | |
| 70498 | <1% | 688 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $5K |
| 97035 | <1% | 96 | $4K | |
| 87476 | <1% | 304 | $4K | |
| 84146 | <1% | 426 | $4K | |
| 80329 | <1% | 2,388 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,874 | $4K |
| ATP09 | <1% | 713 | $4K | |
| 77061 | <1% | 39 | $4K | |
| 83001 | <1% | 366 | $4K | |
| 88304 | <1% | 933 | $3K | |
| 87045 | <1% | 728 | $3K | |
| 84165 | <1% | 661 | $3K | |
| ATP02 | <1% | 884 | $3K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 55 | $3K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 30 | $3K |
| 87338 | <1% | 353 | $3K | |
| 0012A | <1% | 182 | $3K | |
| 87640 | <1% | 448 | $3K | |
| 84460 | <1% | 6,445 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 448 | $3K |
| 80320 | <1% | 3,944 | $3K | |
| 0011A | <1% | 201 | $3K | |
| 84450 | <1% | 5,889 | $3K | |
| 82565 | <1% | 4,518 | $3K | |
| 82550 | <1% | 3,937 | $3K | |
| 12002 | <1% | 13 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,769 | $2K |
| 85018 | <1% | 2,001 | $2K | |
| 85014 | <1% | 1,913 | $2K | |
| 86617 | <1% | 225 | $2K | |
| 97163 | <1% | 78 | $2K | |
| 10060 | <1% | 14 | $2K | |
| 83605 | <1% | 510 | $2K | |
| 82105 | <1% | 184 | $2K | |
| 86431 | <1% | 652 | $2K | |
| 86308 | <1% | 548 | $2K | |
| 80069 | <1% | 2,916 | $2K | |
| 82150 | <1% | 511 | $2K | |
| 43235 | <1% | 12 | $2K | |
| 86039 | <1% | 501 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,294 | $2K |
| 74022 | <1% | 267 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,067 | $2K |
| ATP16 | <1% | 194 | $2K | |
| 80178 | <1% | 641 | $2K | |
| 73590 | <1% | 143 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 35 | $1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 63 | $1K |
| 87469 | <1% | 540 | $1K | |
| 87468 | <1% | 539 | $1K | |
| 86003 | <1% | 53 | $1K | |
| ATP12 | <1% | 277 | $1K | |
| 76857 | <1% | 29 | $1K | |
| 99219 | <1% | 647 | $1K | |
| 84481 | <1% | 150 | $1K | |
| 72070 | <1% | 37 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 164 | $1K |
| 82670 | <1% | 54 | $1K | |
| 87449 | <1% | 144 | $1K | |
| 84156 | <1% | 493 | $1K | |
| 88112 | <1% | 45 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 539 | $983.14 |
| 87107 | <1% | 152 | $980.72 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,449 | $956.52 |
| 84155 | <1% | 899 | $946.95 | |
| 96376 | <1% | 2,416 | $921.52 | |
| 84520 | <1% | 3,154 | $874.45 | |
| 76604 | <1% | 13 | $858.27 | |
| 84100 | <1% | 1,758 | $850.97 | |
| 84550 | <1% | 1,665 | $823.58 | |
| 73090 | <1% | 37 | $817.02 | |
| 87329 | <1% | 142 | $782.03 | |
| 84436 | <1% | 232 | $776.44 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 277 | $738.85 |
| 87328 | <1% | 107 | $705.15 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,111 | $689.02 |
| 86704 | <1% | 106 | $684.45 | |
| 82947 | <1% | 1,681 | $658.66 | |
| 71101 | <1% | 12 | $614.04 | |
| 82040 | <1% | 1,918 | $593.92 | |
| 87522 | Neg quan hep c or qual rna | <1% | 42 | $586.05 |
| 96367 | <1% | 51 | $585.73 | |
| 83718 | <1% | 97 | $574.60 | |
| 86334 | <1% | 42 | $526.33 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 192 | $450.02 |
| 86790 | <1% | 86 | $434.45 | |
| 86708 | <1% | 57 | $417.69 | |
| 87081 | <1% | 63 | $354.52 | |
| 82140 | <1% | 46 | $340.47 | |
| 86665 | <1% | 12 | $323.84 | |
| 86200 | <1% | 40 | $307.06 | |
| 87484 | <1% | 79 | $294.08 | |
| 83615 | <1% | 251 | $285.35 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 70 | $275.04 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 727 | $263.93 |
| 82465 | <1% | 182 | $253.32 | |
| 84154 | <1% | 100 | $243.30 | |
| 82248 | <1% | 1,394 | $240.96 | |
| 86364 | <1% | 671 | $218.61 | |
| 82378 | <1% | 15 | $217.36 | |
| 86255 | <1% | 30 | $208.81 | |
| 82950 | <1% | 49 | $200.15 | |
| 87493 | <1% | 558 | $189.25 | |
| 89051 | <1% | 22 | $176.63 | |
| 86682 | <1% | 25 | $172.05 | |
| 86664 | <1% | 12 | $161.92 | |
| 86663 | <1% | 12 | $148.83 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 103 | $148.20 |
| 86765 | <1% | 13 | $144.65 | |
| 86376 | <1% | 29 | $141.13 | |
| 82247 | <1% | 514 | $136.11 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,589 | $130.15 |
| 94761 | <1% | 230 | $118.05 | |
| 86160 | <1% | 13 | $98.46 | |
| 82310 | <1% | 209 | $88.18 | |
| 84480 | <1% | 12 | $73.05 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 126 | $67.32 |
| 82270 | <1% | 29 | $67.20 | |
| 87075 | <1% | 21 | $60.48 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 64 | $59.18 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,067 | $53.68 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 87 | $42.67 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,356 | $29.28 |
| 85049 | <1% | 18 | $24.54 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,681 | $17.86 |
| 84132 | <1% | 12 | $16.80 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 454 | $16.21 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 2,300 | $15.00 |
| 85041 | <1% | 14 | $13.80 | |
| 85048 | <1% | 14 | $11.55 | |
| 84075 | <1% | 43 | $9.90 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 363 | $0.00 |
| 99001 | 0% | 66 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 22 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 315 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 175 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 16 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 56 | $0.00 |
| 84145 | 0% | 34 | $0.00 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 48 | $0.00 |
| 86231 | 0% | 28 | $0.00 | |
| 99222 | Initial hospital care, per day, moderate complexity | 0% | 30 | $0.00 |
| 80051 | 0% | 303 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 191 | $0.00 |
| 95911 | 0% | 12 | $0.00 | |
| 88341 | 0% | 26 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 23 | $0.00 |
| 80055 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLYNSKEY, JEANNE (VP FINANCE/CHIEF FINANCIAL OFFICIER)